SHR-1819 Files for Approval: The Sixth Ticket In

Before SHR-1819, at least five domestic anti-IL-4Rα antibodies had already reached approval or the marketing-application stage:

Stapokibart (Keymed Biosciences, brand name Kangyuda) was approved in China in 2024 — the first domestic antibody against this target — and has since secured three indications: moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and moderate-to-severe seasonal allergic rhinitis in adults, the last being the world’s first approval of an anti-IL-4Rα antibody for seasonal allergic rhinitis. All three indications were included in the 2025 National Reimbursement Drug List (NRDL), effective January 1, 2026.

GR1802 (Zhixiang Jintai; Chinese generic name 泰利奇拜单抗): its adult moderate-to-severe atopic dermatitis application was accepted in September 2025, and its adult seasonal allergic rhinitis application in February 2026; reports indicate the atopic dermatitis filing was withdrawn and resubmitted, accepted again in August 2026.

MG-K10 (Maiji Bio; Chinese generic name 柯美奇拜单抗): its adult moderate-to-severe atopic dermatitis application was accepted on October 30, 2025, and its seasonal allergic rhinitis application on April 23, 2026, with a publicly stated long-acting, once-every-four-weeks positioning.

Rademikibart (Simcere Pharmaceutical, originated by Connect Biopharma; Chinese generic name 乐德奇拜单抗): its atopic dermatitis application had been accepted, then was voluntarily withdrawn in April 2026 and resubmitted. AK120 (Akeso Biopharma; Chinese generic name 曼多奇单抗): its atopic dermatitis application was accepted in February 2026, with the company stating that the Phase 3 primary endpoint, key secondary endpoints, and multiple prespecified secondary endpoints were all met.

Public information as of 2026-09-04. Ranked against these five, SHR-1819 is at least the sixth domestic innovative drug against this target to reach approval or regulatory review — and the queue ahead holds not two but at least four still under review.

SHR-1819 is Hengrui’s in-house recombinant humanized anti-human IL-4Rα monoclonal antibody. By blocking IL-4Rα it shuts down both IL-4 and IL-13 signaling — the classic type 2 inflammation playbook. It is not a bispecific, not an antibody-drug conjugate, and involves no delivery platform: just a conventional subcutaneously injected mAb.

The Phase 2 study, published in BMC Medicine in 2026, ran across 22 centers in China. 157 patients were randomized 1:1:1:1 to 300 mg every two weeks, 600 mg every two weeks, 600 mg every four weeks, or placebo, with the 300 mg Q2W arm using a 600 mg loading dose; background emollient use was mandatory throughout. At week 16, EASI-75 response rates were 69.2%, 75.0%, and 85.4% versus 37.8% for placebo — differences of 31.6, 37.0, and 47.4 percentage points, with nominal p-values of 0.006, 0.001, and <0.001. EASI-90 was 53.8%, 57.5%, and 63.4% versus 16.2%; the proportion achieving IGA 0/1 with at least a 2-point improvement from baseline was 53.8%, 50.0%, and 65.9% versus 16.2%.

Three caveats on how to read these numbers.

First, the Phase 2 had no multiplicity control; the paper reports “nominal p-values” throughout — read them as directional, not confirmatory. Second, the placebo response of 37.8% is on the high side; mandatory background emollients may be one reason, but sample size, patient mix, and trial setting matter too — and the paper contains a detail worth noting: 32.4% of placebo patients received rescue therapy, versus 0% in the 600 mg Q4W arm. Third, the authors themselves state explicitly that cross-trial comparisons should be made with caution.

That third point matters most, because it bears on this asset’s most hoped-for selling point.

On safety: treatment-related adverse events occurred in 45.8% of Phase 2 patients versus 40.5% on placebo; any adverse events were 92.3%, 90.0%, and 80.5% across the three dose arms versus 81.1% for placebo. The most common were upper respiratory tract infection at 22.5% (placebo 10.8%) and injection-site reactions at 10.8% (placebo 5.4%). Conjunctivitis occurred in 7 patients (5.8%), all in treatment arms, with 6 judged treatment-related. Serious adverse events were 5.8% in treatment arms versus 8.1% for placebo; one patient in the 600 mg Q4W arm died of cerebral herniation, judged unrelated to treatment. Anti-drug antibody positivity was 7.7%, 5.0%, and 9.8% across the three dose arms.

These numbers come from a 157-patient Phase 2 — fine for directional reads, not for labeling. The true safety profile awaits the 652-patient Phase 3, for which not a single number has been disclosed.

One more detail: Phase 1 PK showed time to peak of 4–7 days after single subcutaneous doses from 60 mg to 720 mg, with half-life of 2.88–5.97 days in the 120–720 mg range. Phase 2 steady-state data show both 600 mg Q4W and Q2W maintain stable drug concentrations, but Phase 3 steady-state exposure and trough levels remain undisclosed.

This is a company with slightly declining revenue, pressured profits, and an R&D engine that hasn’t slowed. In that state, any new molecule consuming resources has to answer “why this one.”

On public trial registries, 13 studies are associated with SHR-1819, spanning six areas: adult atopic dermatitis, adolescent atopic dermatitis, atopic dermatitis in children aged 6 months to 5 years, prurigo nodularis, chronic spontaneous urticaria, and seasonal allergic rhinitis. Two are Phase 1 studies in healthy volunteers, one of which (NCT04772365) carries an “asthma” disease tag while the study title and eligibility criteria show healthy subjects — it was early PK and safety exploration oriented toward asthma, not a study in asthma patients.

Of these 13, 12 are in China; the only ex-China study is a 2020 Phase 1 in healthy volunteers in Australia. The pivotal studies were all conducted in China — there is no US/EU data package.

Per trial registries, searched 2026-09-04. Estimated completion dates are sponsor-reported estimates, not data-release dates.

Hengrui’s announcement cites Evaluate Pharma data: combined 2025 global sales of dupilumab and stapokibart of approximately USD 18.076 billion. By Sanofi’s own 2025 reporting, dupilumab’s global sales reached EUR 15.7 billion. This is an enormous category.

But for the sixth domestic anti-IL-4Rα antibody to enter Chinese regulatory review, that number has limited reference value. Dupilumab’s US core compound patent, with term extension, runs to March 2031; Sanofi has stated it has an “active defense plan” to extend exclusivity, alongside extensive formulation and use patents and pending applications. So “patent expiry approaching” cannot be read directly as “the global competitive window has opened” — or “has closed” — it only means that over the coming years the global market will face simultaneous pressure from biosimilars and novel molecules, and a sixth-in-line product with a China-only data package has limited pricing power in that squeeze.

The more realistic call: SHR-1819’s ex-China value can only be realized through regional licensing — and more likely in price-competitive markets than in the US/EU core markets.

From a regulatory standpoint this is a well-formed asset: the Phase 3 used internationally standard co-primary endpoints, enrolled 652 patients, and is backed by a 157-patient dose-finding Phase 2 plus a 79-patient open-label extension — a complete data package. The marketing application is accepted and in the review channel.

The restraint needed: don’t read “well-formed” as “low-risk.” No Breakthrough Therapy designation or priority review has been announced, so launch timing should not be built on accelerated-review assumptions. But the Phase 3 quantitative results, CMC package, and site-inspection outcomes are all still invisible — it is too early to call regulatory uncertainty low.

Two relatively open registration paths exist. One is younger populations: the adolescent Phase 3 started in March 2026, and the clinical trial approval for children aged 6 months to 5 years was granted in May 2026. To be precise — dupilumab is already approved in China for moderate-to-severe atopic dermatitis in patients 6 months and older, and young children already dose every four weeks — so the accurate framing is “no domestic peer covers this age group yet,” not “no competitor covers it.”

The other is indications with no approved domestic peer: the seamless Phase 2/3 in prurigo nodularis is underway, and a clinical trial approval for chronic spontaneous urticaria has been granted (no public registry record found for that one). The cost is time — the prurigo nodularis study’s estimated primary completion date is October 2028, and that is the sponsor’s registry estimate, not a data-release date.

Hengrui-type companies run on this asset logic: the molecule need not be the best; the commercial platform can turn a middling molecule into decent revenue. The question is whether that leverage transfers directly to this asset.

The answer: not directly.

Hengrui’s commercial strengths sit in oncology, anesthesia, and contrast imaging. Prescriptions for moderate-to-severe AD biologics concentrate in dermatology departments of tier-3 hospitals; prurigo nodularis and chronic urticaria sit in dermatology too, and seasonal allergic rhinitis in ENT and allergy departments. These specialties barely overlap Hengrui’s existing strongholds, and public materials show no marketed blockbuster in dermatology/autoimmune that could amplify this launch.

The good news: that investment isn’t for one product. Type 2 inflammation spans dermatology, ENT, respiratory, and allergy; SHR-1819’s six indication directions cover most of that territory. Once the team is built, it can be reused across subsequent indications and molecules. From this angle, it looks less like buying a high-return single product and more like buying a ticket into the type 2 inflammation arena.

That also dictates how the revenue model should be built: the reimbursement price anchor is set, competition is dense, and there is no NRDL coverage in year one — peak sales should be modeled as “low price, high penetration, stacked indications,” not as innovative-drug premium pricing. What really drives the revenue curve is three things: how many indications the label can stack, the NRDL cadence for each, and long-term treatment persistence.

On persistence, one observable action: in June 2026 Hengrui completed a 160-patient bioavailability study of delivery devices, comparing a prefilled syringe with another delivery device. That proves device development is moving, but it is not enough to conclude a final at-home self-administration option will exist — the registry lists the second arm as “Artificial Intelligence (AI) Group,” which in a device context is most likely an erroneous expansion of the auto-injector abbreviation; the registry wording itself is unreliable. More telling of intent is a line in Hengrui’s acceptance announcement: “the core demand of AD clinical treatment has gradually shifted toward the dual need for higher response rates and better dosing convenience.”

Manufacturing is not the bottleneck. SHR-1819 is a conventional humanized IgG mAb — no linker IP issues as with ADCs, no delivery systems as with nucleic acid drugs, none of the supply-chain complexity of cell therapy — and Hengrui already has multiple biologics marketed in China, so commercial mAb manufacturing and quality systems are in place. The caveat: public materials disclose nothing on this product’s specific manufacturing site, capacity, or inspection history — the above is inferred from company scale and modality. The device supplier is also undisclosed, and single-source device supply is a common hidden risk for such products.

On portfolio position: since 2023 Hengrui has completed 13 ex-China licensing deals with a combined potential value of about USD 42 billion. A common misread to flag: that USD 42 billion is the sum of milestone caps across deals, not cash in hand; licensing income actually recognized in H1 2026 was RMB 1.422 billion.

The largest was the July 2025 GSK collaboration: ex-Greater-China exclusive rights to HRS-9821 plus options on up to 11 additional programs, with USD 500 million in combined upfront payments and up to ~USD 12 billion if all options are exercised and milestones met, spanning respiratory, immunology & inflammation, and oncology. Hengrui leads development through Phase 1 and retains Greater China rights.

From a portfolio-governance angle, R&D budget is not the constraint — H1 R&D spending was RMB 4.605 billion, up nearly 19%. The real constraint is prioritization. Cumulative R&D of RMB 385.7 million is mid-to-low by Hengrui’s scale; its resource competitors aren’t other molecules in the same therapeutic area but the oncology and metabolic lines. It looks like “routine advancement,” not a “key bet.”

This is a beautifully executed program. Enrolling 652 Phase 3 patients in 26 months, 13 studies across six indication directions, all three age groups covered, the delivery-device bridging done ahead of time, and just 9 days from Phase 3 completion to NDA acceptance — these are large-pharma capabilities, and Hengrui’s genuine strengths. The one thing a latecomer can compress is time, and Hengrui did exactly that.

But execution can’t fix positioning. By the time this molecule entered the review channel, one domestic peer with NRDL listing and at least four domestic peers under review were already ahead of it, while the originator holds the full age spectrum from 6 months to adults. Prices are set, the specialty team must be built from scratch, and reimbursement is still two years away.

Three milestones are worth watching next: first, the Phase 3 quantitative results and the final filed dosing regimen — which decide whether “once every four weeks” becomes label differentiation; second, the review cadence and any sign of an accelerated pathway; third, the seasonal allergic rhinitis Phase 3 readout expected around December 2026 — the nearest incremental signal.